XML 60 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statement of Stockholder's Equity (USD $)
Total
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Accumulated Other Comprehensive Income (Loss)
Beginning Balance at Dec. 31, 2009 $ 30,495,067 $ 118,349 $ 316,009,930 $ (286,027,935) $ 394,723
Beginning Balance, Shares at Dec. 31, 2009   11,834,958      
Net loss (25,243,551)     (25,243,551)  
Unrealized gain (loss) on foreign currency translation (268,810)       (268,810)
Change in unrealized gain (loss) on securities available-for-sale (6,191)       (6,191)
Issuance of common stock and warrants, net of issuance cost of $480,835, $1,522,083 and $900,992 in 2010, 2011 and 2012 respectively, shares   847,520      
Issuance of common stock and warrants, net of issuance cost of $480,835, $1,522,083 and $900,992 in 2010, 2011 and 2012 respectively 7,279,234 8,475 7,270,759    
Common stock issued pursuant to employee benefit plan, shares   18,488      
Common stock issued pursuant to employee benefit plan 232,229 185 232,044    
Compensation expense from grant of options, restricted stock units and stock (fair value) 3,697,405   3,697,405    
Exercise of employee and director stock options, shares 3,451 3,451      
Exercise of employee and director stock options 19,802 35 19,767    
Exercise and net settlement of restricted stock units, shares   53,370      
Exercise and net settlement of restricted stock units (483,406) 534 (483,940)    
Stock retired from settlement agreement, shares   (26,500)      
Stock retired from settlement agreement (241,150) [1] (265) (240,885)    
Ending Balance at Dec. 31, 2010 15,480,629 127,313 326,505,080 (311,271,486) 119,722
Ending Balance, Shares at Dec. 31, 2010   12,731,287      
Net loss (21,328,536)     (21,328,536)  
Unrealized gain (loss) on foreign currency translation 40,032       40,032
Change in unrealized gain (loss) on securities available-for-sale (119,041)       (119,041)
Issuance of common stock and warrants, net of issuance cost of $480,835, $1,522,083 and $900,992 in 2010, 2011 and 2012 respectively, shares   9,525,116      
Issuance of common stock and warrants, net of issuance cost of $480,835, $1,522,083 and $900,992 in 2010, 2011 and 2012 respectively 13,792,340 95,251 13,697,089    
Common stock issued pursuant to employee benefit plan, shares   35,164      
Common stock issued pursuant to employee benefit plan 164,896 352 164,544    
Compensation expense from grant of options, restricted stock units and stock (fair value), shares   32,631      
Compensation expense from grant of options, restricted stock units and stock (fair value) 3,096,043 326 3,095,717    
Exercise of employee and director stock options, shares 1,692 1,692      
Exercise of employee and director stock options 2,386 17 2,369    
Exercise and net settlement of restricted stock units, shares   102,065      
Exercise and net settlement of restricted stock units (403,625) 1,021 (404,646)    
Ending Balance at Dec. 31, 2011 10,725,124 224,280 343,060,153 (332,600,022) 40,713
Ending Balance, Shares at Dec. 31, 2011   22,427,955      
Net loss (28,491,153)     (28,491,153)  
Unrealized gain (loss) on foreign currency translation 151,125       151,125
Change in unrealized gain (loss) on securities available-for-sale 1,339       1,339
Issuance of common stock and warrants, net of issuance cost of $480,835, $1,522,083 and $900,992 in 2010, 2011 and 2012 respectively, shares   14,546,042      
Issuance of common stock and warrants, net of issuance cost of $480,835, $1,522,083 and $900,992 in 2010, 2011 and 2012 respectively 28,725,507 145,460 28,580,047    
Common stock for external services, shares   102,058      
Common stock for external services 175,235 1,021 174,214    
Common stock issued pursuant to employee benefit plan, shares   129,893      
Common stock issued pursuant to employee benefit plan 97,017 1,299 95,718    
Compensation expense from grant of options, restricted stock units and stock (fair value), shares   182,502      
Compensation expense from grant of options, restricted stock units and stock (fair value) 2,655,884 1,825 2,654,059    
Exercise of employee and director stock options, shares 3,629 3,629      
Exercise of employee and director stock options 3,629 36 3,593    
Exercise and net settlement of restricted stock units, shares   114,226      
Exercise and net settlement of restricted stock units (59,090) 1,142 (60,232)    
Ending Balance at Dec. 31, 2012 $ 13,984,617 $ 375,063 $ 374,507,552 $ (361,091,175) $ 193,177
Ending Balance, Shares at Dec. 31, 2012   37,506,305      
[1] On April 1, 2009, we acquired the operations of Stem Cell Sciences Plc (SCS), which changed its name to Asset Realization Company Limited. Pursuant to the acquisition agreement, 53,000 shares were placed into an escrow for a twelve month period to satisfy any indemnification obligations owed to us by SCS. On August 19, 2010, we entered into a settlement agreement with SCS in which the parties agreed to the release of half the escrowed shares to SCS and half to us in full satisfaction of our claims for indemnification, and both parties waived all other claims, known and unknown, against the other. The 26,500 shares returned to us are being treated as retired and no longer outstanding. We have recorded approximately $227,000 as other income, which was the value of these shares based on the closing price of $9.10 per share on August 19, 2010, and net of amounts already accrued for potential claims against the escrowed shares.